Leishmaniasis in humans: drug or vaccine therapy?
M Ghorbani, R Farhoudi - Drug design, development and therapy, 2017 - Taylor & Francis
Leishmania is an obligate intracellular pathogen that invades phagocytic host cells.
Approximately 30 different species of Phlebotomine sand flies can transmit this parasite …
Approximately 30 different species of Phlebotomine sand flies can transmit this parasite …
Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions
Abstract Liposomal amphotericin B (AmBisome®; LAmB) is a unique lipid formulation of
amphotericin B. LAmB is a standard of care for a wide range of medically important …
amphotericin B. LAmB is a standard of care for a wide range of medically important …
Review and analysis of FDA approved drugs using lipid-based formulations
R Savla, J Browne, V Plassat, KM Wasan… - Drug development and …, 2017 - Taylor & Francis
Lipid-based drug delivery systems (LBDDS) are one of the most studied bioavailability
enhancement technologies and are utilized in a number of US Food and Drug …
enhancement technologies and are utilized in a number of US Food and Drug …
[HTML][HTML] Lipid systems for the delivery of amphotericin B in antifungal therapy
C Faustino, L Pinheiro - Pharmaceutics, 2020 - mdpi.com
Amphotericin B (AmB), a broad-spectrum polyene antibiotic in the clinic for more than fifty
years, remains the gold standard in the treatment of life-threatening invasive fungal …
years, remains the gold standard in the treatment of life-threatening invasive fungal …
Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries
A Loyse, H Thangaraj, P Easterbrook… - The Lancet infectious …, 2013 - thelancet.com
Cryptococcal meningitis is the leading cause of adult meningitis in sub-Saharan Africa, and
contributes up to 20% of AIDS-related mortality in low-income and middle-income countries …
contributes up to 20% of AIDS-related mortality in low-income and middle-income countries …
Recent developments and future prospects in the treatment of visceral leishmaniasis
Limited therapeutic options in visceral leishmaniasis (VL) make the treatment of this
neglected disease very challenging. In addition to this, long treatment duration and toxic …
neglected disease very challenging. In addition to this, long treatment duration and toxic …
Liposomal amphotericin B for treatment of leishmaniasis: from the identification of critical physicochemical attributes to the design of effective topical and oral …
F Frézard, MMG Aguiar, LAM Ferreira, GS Ramos… - Pharmaceutics, 2022 - mdpi.com
The liposomal amphotericin B (AmB) formulation, AmBisome®, still represents the best
therapeutic option for cutaneous and visceral leishmaniasis. However, its clinical efficacy …
therapeutic option for cutaneous and visceral leishmaniasis. However, its clinical efficacy …
Nanostructured delivery systems with improved leishmanicidal activity: a critical review
N Bruni, B Stella, L Giraudo, C Della Pepa… - International journal …, 2017 - Taylor & Francis
Leishmaniasis is a vector-borne zoonotic disease caused by protozoan parasites of the
genus Leishmania, which are responsible for numerous clinical manifestations, such as …
genus Leishmania, which are responsible for numerous clinical manifestations, such as …
Design of amphotericin B oral formulation for antifungal therapy
M Liu, M Chen, Z Yang - Drug delivery, 2017 - Taylor & Francis
Amphotericin B (AmB) remains the “gold standard” for systemic antifungal therapy, even
though new drugs are emerging as the attractive antifungal agents. Since AmB has …
though new drugs are emerging as the attractive antifungal agents. Since AmB has …
Formulation of amphotericin B in PEGylated liposomes for improved treatment of cutaneous leishmaniasis by parenteral and oral routes
GS Ramos, VMR Vallejos, GSM Borges, RM Almeida… - Pharmaceutics, 2022 - mdpi.com
Liposomal amphotericin B (AmB) or AmBisome® is the most effective and safe therapeutic
agent for visceral leishmaniasis (VL), but its clinical efficacy is limited in cutaneous …
agent for visceral leishmaniasis (VL), but its clinical efficacy is limited in cutaneous …